cyrilzakka/clinical-trials huggingface dataset:
Effect of Chest Compression on Respiratory Mechanics in ARDS Patients

In some ARDS patients, a mild chest compression (5 kg) improves lung compliance.

We aim to determine wether such an improvement is due to a better recruitment or to a reduction of overdistension


Eligibility Criteria:
Inclusion Criteria:

* ARDS (Berlin definition)
* Age \>18y
* under invasive mechanical ventilation

Exclusion Criteria:

* people protected by the law
Validation of Study in Respiratory Physiology and it Interactions

The aim of the study was to validate tools of physiological signal processing and interpretation on healthy human volunteers in order to improve the understanding in respiratory physiology and its interactions with heart function, and swallowing.


Eligibility Criteria:
Inclusion Criteria:

* healthy subject
* between 18 and 60 years old

Exclusion Criteria:

* patient
* person protected by the law
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis

To compare the safety and effectiveness of fluconazole and amphotericin B, alone or in combination with flucytosine, as treatment for acute cryptococcal meningitis.


Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* Immunosuppressant therapy.
* Antiviral such as zidovudine.
* Radiation therapy for mucocutaneous Kaposi's sarcoma.
* Prophylaxis for Pneumocystis carinii pneumonia (PCP) including aerosol pentamidine.

Concurrent Treatment:

Allowed:

* Radiation therapy for mucocutaneous Kaposi's sarcoma.

Written informed consent must be obtained for each patient, either from the patient himself or from the patient's legal guardian.

* No prior systemic antifungal therapy for cryptococcosis.
* Relapse after prior therapy.
* Success of prior therapy must have been documented by negative cerebrospinal fluid (CSF) culture at the end of therapy. Following prior therapy, such patients may not have received more than 1 mg/kg/wk amphotericin B in the 4 weeks before entry into study.

Prior Medication:

Allowed:

* Immunosuppressant therapy.
* Antivirals such as zidovudine (AZT).
* Prophylaxis for Pneumocystis carinii pneumonia (PCP) including aerosol pentamidine.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

* Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
* History of allergy to or intolerance of imidazoles, azoles, or amphotericin B.
* Moderate or severe liver disease.
* Comatose.
* Unlikely to survive more than 2 weeks.
* Any exceptions to these prohibitions of concomitant medications must be approved by Pfizer Central Research.

Concurrent Medication:

Excluded:

* Coumadin-type anticoagulants.
* Oral hypoglycemics.
* Barbiturates.
* Phenytoin.
* Immunostimulants.
* Investigational drugs or approved (licensed) drugs for investigational indications.
* Any exceptions to these prohibitions of concomitant medications must be approved by Pfizer Central Research.
* Excluded within 4 weeks of study entry:
* Received more than 1 mg/kg/wk amphotericin B.

Concurrent Treatment:

Excluded:

* Lymphocyte replacement.

Patients with the following are excluded:

* Evidence of acute or chronic meningitis based upon any etiology other than cryptococcosis.
* History of allergy to or intolerance of imidazoles, azoles, or amphotericin B.
* Moderate or severe liver disease.
* Comatose.
* Unlikely to survive more than 2 weeks.

Prior Medication:

Excluded:

* Coumadin-type anticoagulants.
* Oral hypoglycemics.
* Barbiturates.
* Phenytoin.
* Immunostimulants.
* Investigational drugs or approved (licensed) drugs for investigational indications.
* Excluded within 4 weeks of study entry:
* More than 1 mg/kg/wk amphotericin B.

Prior Treatment:

Excluded:

* Lymphocyte replacement.
LH Hormone Pulsation in the Luteal Phase in GnRH Antagonist IVF Cycles Triggered by GnRH Agonist for Final Oocyte Maturation

Monitoring the LH pulsatility during the Luteal phase in GnRH antagonist IVF cycles triggered by GnRH agonist for final oocyte maturation.

About two decades ago the GnRH antagonist has been used in IVF cycles to prevent premature LH surge. In recent review GNRH antagonist has been found comparable to GnRH agonist in term of live birth rate but with reduced risk of OHSS. another advantage of using GnRH antagonist is the ability to use GnRH agonist for final oocyte maturation which has been shown to nearly eliminate the risk of OHSS. The exact mechanism of this risk reduction is still unknown.

Our aim is to do a frequent blood tests every 20 minutes for 6 hours duration in the day of ovum pick up or the day of embryo transfer to measure the level of LH, estradiol and progesterone in women triggered with GnRH agonist for final oocyte maturation.

Eligibility Criteria:
Inclusion Criteria:

* age: 18-42 years old BMI \< 32 kg/m2

Exclusion Criteria:

* Hypogonadotropic hypogonadism
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer

This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying early stages of pancreatic cancer, as well as people at high-risk.The study also aims to provide a platform for development of an interventional protocol for early detection of PDAC.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 year
* Able to provide written informed consent
* Meets criteria as a High-Risk Individual as defined by protocol

Exclusion Criteria:

* Individual who has a personal history of pancreatic ductal adenocarcinoma (PDAC)
* History of total pancreatectomy
Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial

This placebo-controlled, double-blind, randomized pilot clinical trial will evaluate atomoxetine (Strattera®) for the treatment of cocaine dependence. Cocaine-dependent individuals, who are healthy and are seeking treatment for their substance abuse, will be randomized to receive either atomoxetine (n=25) or a matched-placebo (n=25) during a trial lasting 12 weeks; there will be a double-blind, ascending dose lead-in order to achieve maintenance on the assigned active dose safely. Contingency management procedures will be used to reinforce attendance and compliance with study procedures. Primary outcome measures will include urinalysis data assessing cocaine use.


Eligibility Criteria:
Inclusion Criteria:

* Seeking treatment for cocaine dependence
* Must have used cocaine in the past 30 days

Exclusion Criteria:

* Physical dependence on any drug requiring medical management
* Any major medical or psychiatric disorder that would be contraindicated for participation
* Cardiovascular disease
* Seizures or significant head injuries
* Currently taking atomoxetine
* Pregnant or breast-feeding
Development of a Segmental Bioelectrical Impedance Spectroscopy Device for Body Composition Measurement

A device for measuring body composition with a small electric current, at 200 μA, (bioelectrical impedance analysis, or BIA) was designed. The goal of this study is to validate the device against several existing devices using the same method of measuring body composition with a small electric current.

The measurement of individual segments, instead of the body as a whole, with BIA has not been fully explored. The prototype device is capable of directly measuring multiple body segments (arm, trunk, and leg) simultaneously, and the final version will be able to provide composition about each segment and the body as a whole. Current devices on the market are not capable of this.

The reference devices will be used to measure segments as well, and the raw measurements will be compared. The Multiscan 5000 provides segmental body composition for the arm or leg, but requires measuring it separately. The SFB7 is designed only for measuring the whole body, but the raw impedance measurement data from the SFB7 can be used for comparison, as the impedance magnitudes of individual segments will be within its measurement range. The Seca 514 doesn't directly measure segments, but it can provide segmental data by measuring from hand to foot, then from hand to hand, and finally from foot to foot. It then uses these measurements, and assumptions about the subject to provide segmental composition data.

Eligibility Criteria:
Inclusion Criteria:

* Students from Georgia Southern University

Exclusion Criteria:
Post-operative Functional Disability in Unrecognized Cognitive Impairment (POF) Study

This is a prospective multicenter cohort study, which will determine the prevalence of preoperative cognitive impairment (CI) using the Modified Telephone Interview for Cognitive Status (TICS-M), Eight-items interview to Differentiate Aging and Dementia (AD8), Telephone Montreal Cognitive Assessment (T-MoCA), and a single cognitive question from the Centers for Disease Control and Prevention (CDC). We would also determine the (1) the degree of agreement in screening results between each cognitive screening tool, (2) risk factors associated with screening positive for CI on each tool, and (3) the prevalence and/or trajectory of postoperative delirium, sleep disturbances, functional disability, instrumental activities of daily living (IADL), depression, quality of health, frailty, and pain in older surgical patients and its association with CI. This study will target older patients from the pre-operative clinics at Toronto Western Hospital and Mount Sinai Hospital (MSH), Toronto. Research staff will identify eligible patients who are scheduled for elective non-cardiac surgery. Written informed consent to participate in the study will be obtained from all patients.

The primary aim of this study is to (1) determine the prevalence of CI preoperatively in older surgical adults using virtual or telephone cognitive instruments, (2) determine the degree of agreement in screening results between each cognitive screening tool, and (3) explore the prevalence and trajectory of preoperative and postoperative outcomes and its association with CI. The outcomes include functional disability, IADL, sleep disturbances, quality of health, frailty, pain and depression.

In a preoperative assessment 1-30 days prior to their scheduled surgery, patients will be asked via telephone to complete TICS-M and T-MoCA and an online questionnaire, including the AD8, CDC single cognitive question, World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0), IADL, EuroQol 5 Dimension (EQ-5D-5L), Geriatric Depression Scale (GDS), 5-item FRAIL questionnaire, (FRAIL), visual analog pain scale (VAS pain), Single-item Sleep Quality Scale (SQS), Pittsburgh Sleep Quality Index (PSQI), and STOP questionnaire. These questionnaires will be repeated at follow-up visits at 30-, 90-, and 180-days post-surgery. At the hospital on post-operatively days 1-3, the Confusion Assessment Method (CAM), SQS, and VAS pain will be administered during the in-person visit. Chart review of delirium will also be conducted during patients' stay at the hospital.

Eligibility Criteria:
Major Inclusion Criteria:

* patients ≥ 65 years old;
* patients scheduled for elective non-cardiac surgery
* able to be contacted by telephone for follow up.

Major Exclusion Criteria:

* patients with previous dementia diagnosis,
* patients scheduled for outpatient surgery,
Comparison of the Proprioceptive Neuromuscular Facilitation and Mobilization In Subacromial Impingement Syndrome

Aim of the study was to compare the effectiveness of Proprioceptive Neuromuscular Facilitation (PNF) exercises and Shoulder Mobilization (SM) on pain, range of motion (ROM), functionality, and muscle strength in patients with Subacromial Impingement Syndrome (SIS). Patients received 20 sessions (for 4 weeks) under the supervision of a physiotherapist. Patients were evaluated at baseline, at week two, at week four, and at week sixteen.

Aim of the study was to compare the effectiveness of Proprioceptive Neuromuscular Facilitation (PNF) exercises and Shoulder Mobilization (SM) on pain, range of motion (ROM), functionality, and muscle strength in patients with Subacromial Impingement Syndrome (SIS). Forty-four patients were divided into three groups as Group I: Conventional physiotherapy receiving group (control group; n=14), Group II: Conventional physiotherapy + PNF exercises receiving group (PNF group; n=15), and Group III: conventional physiotherapy + SM receiving group (SM group; n=15). Pain, ROM, muscle strength, and functionality were evaluated by using visual analog scale (VAS), goniometer, push-pull dynamometer, Constant-Murley score and The Disabilities of the Arm, Shoulder and Hand (DASH) Score respectively. Patients received 20 sessions in total under supervision of a physiotherapist. Patients were evaluated at baseline, at week two, at week four, and at week sixteen.

Eligibility Criteria:
Inclusion Criteria:

* Aged between 25-65 years old,
* Having the diagnosis of Subacromial Impingement Syndrome (SIS),
* Having shoulder pain at least for four weeks

Exclusion Criteria:

* Having a neuromuscular disease,
* Pregnancy,
* History of cancer,
* Unstable angina,
* Having pulmonary and/or vascular problems,
* History of surgery at neck, shoulder, elbow or/and hand,
* Having communication problems
* Having systemic anti-inflammatory joint diseases
* Being contraindicated for electrical stimulation and/or exercise
* Having cervical disc herniation or radiculopathy
* History of physiotherapy on the same shoulder due to SIS,
* A history of corticosteroid injection in the last three months,
* Any orthopedic, rheumatologic, or congenital condition that effects the targeted shoulder
Evaluation of the Impact of a Multidimensional ICT Intervention on the Quality of Life of Breast Cancer Survivors

mACMA is a pilot study that is developed for breast cancer survivors of the Hospital Clinic of Barcelona. The objective of this study is to evaluate the progress in quality of life through the introduction of a mobile phone App that allows for symptom tracking, physical activity tracking and a calendar of patient-oriented events organized by patient organizations. This study is a two-arm randomized clinical trial.

This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 875351.


Eligibility Criteria:
Inclusion Criteria:

* Previous diagnostic of breast cancer
* Free of disease at the time of randomization
* Signed consent form
* Possession of a smartphone and ability to use smartphone applications
* Patients belonging to the ACMA group o being treated at Hospital Clínic
* Without diagnosis of neurodegenerative disorders that prevent participation in the study

Exclusion Criteria:

* Acute process of cancer at the moment of recruitment
* Active treatment for cancer (chemotherapy, radiotherapy)
* Comorbidities such as heart failure NYHA class 4, COPD,...
* Inability to give informed consent
ESCAPE (Evaluating Surge Capacity And PrEparedness)

The ESCAPE study intends to assess the possibility of recruiting students as surge capacity work force in hospitals in the event of a major medical incident such as an epidemic or pandemic.

The ESCAPE study intends to assess the possibility of recruiting students as surge capacity work force in hospitals in event of a major medical incident such as an epidemic or pandemic. The study consists of two parts:

* To identify the need for student surge capacity work force in relevant departments most affected by major medical incidents (e.g. Emergency Department, Intensive Care Unit, etc.). This part also raises the question of which tasks can be delegated to such a surge capacity workforce and which training may be required to prepare for such tasks.
* To identify and quantify the willingness of students to enroll as surge capacity workforce, identifying which tasks they would be willing to perform and which organisational framework is required for their work (training, insurance, pay, etc.).

Both subparts as planned as questionnaires to be completed voluntarily and anonymously.

Eligibility Criteria:
Inclusion Criteria:

* Medical experts (heads of departements and other management positions) working in selected departments that are typically affected by major medical incidents at the time of questionnaire roll-out.
* Medical students \>18 years of age of any year enrolled in the year 2023-2024 in any of the 38 medical faculties in Germany

Exclusion Criteria:

* none, as questionnaire participation was achieved by invitation of eligible volunteers
12-week Exercise-based Program in Myocardial Revascularization Subjects

To determine if a 12-week physical exercise program (12-WPEP), after percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) with different left ventricular ejection fraction (LVEF) might improve the health-related quality of life (HRQOL).

Percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG) are interventions that can reduce cardiovascular symptoms such as dyspnea and angina. The life quality and the functional capacity improved in the subjects who underwent surgery. However, new cardiac events, death and obstruction of the bypass placed can exist. To diminish these risks, national and international guides recommend cardiac rehabilitation (CR) for people with coronary disease, who have suffered a myocardial infarction and are subjected to CABG and PCI. A 20-30% reduction of morbidity and mortality can be obtained with the use of CR. According to the European Society of Cardiology (ESC), the American Heart Association (AHA) and the American College of Cardiology (ACC), CR is a recommendation Class Type I, in subjects treated with PCI and CABG. This includes prescribed physical exercises, education, and counseling to modify the effects of coronary heart disease and improve long-term survival. Exercise-based cardiac rehabilitation is an effective and safe therapy to be used in the management of clinically stable patients following PCI or CABG. The maximum oxygen uptake (VO2max) is improved by the exercise carried out during CR, optimizing the physical condition and health-related quality of life (HRQOL).

The HRQOL is considered a very important criterion used to evaluate the effectiveness of different treatments in patients with coronary disease, and is defined by subjective evaluation regarding the current activities of health care and health promotion; it indicates the personal perception in various aspects such as the recovery of the functional, labor, sexual and social capabilities of the patient, factors that have great importance in the evolution of the patient; this perception is considered the best indicator of quality of life, and has become a key concept for the decision making. In this study, we will evaluate the effects of a physical exercise program in the health-related quality of life of subjects following CABG or PCI with normal and reduced left ventricular ejection fraction (LVEF)

Eligibility Criteria:
Inclusion Criteria:

- CABG or post-PCI subjects and agreed to participate by signing the informed consent form.

Exclusion Criteria:

* Subjects with musculoskeletal limitations for physical exercise, untreated ventricular arrhythmias, with the presence of residual pericardial effusion, history of intermittent claudication or left ventricular ejection fraction \<30% measured by 2D-echocardiography
Research on Individualized Treatment for Alcoholism

The purpose of this study was to compare the effects of two psychosocial treatments that differed in scope and intensity (Broad Spectrum Treatment and Motivational Enhancement Treatment) combined with 3 or 6 months of treatment with naltrexone on alcohol drinking behaviors in alcohol dependent patients.


Eligibility Criteria:
Inclusion Criteria:

* men and women between the ages of 21-65
* current DSM-IV diagnosis of alcohol dependence
* abstinent for a minimum of 3 and maximum of 21 days prior to treatment initiation
* able to participate in an 18-month outpatient study
* live within a one hour or less commute to Fairbanks
* fluent in English
* women of child-bearing potential must have a negative pregnancy test and use effective contraceptive methods.
* score as contemplators or greater on the Readiness For Change Scale

Exclusion Criteria:

* severe hepatic disease (gGGT, SGOT or other liver functions greater than 4 times normal)
* opiate use (for any reason) in the last 14 days or a history of opioid dependence in the past year
* pregnant or lactating females or those unwilling to use birth control
* inability, according to the opinion of the interviewer, to follow medication instructions and safety precautions
* comorbid substance dependence (but not abuse) diagnosis in the past 6 months, excluding nicotine or marijuana dependence
* concomitant use of medications intended to decrease drinking (e.g. disulfiram)
* meeting current DSM criteria for bipolar disorder, schizophrenia, bulimia/anorexia, dementia, major depression
Epidemiology of Risk Factors for Hospital-acquired Pneumonia (HAP) in Intensive Care Unit (ICU) Patients

A retrospective, observational study compiled data from all consecutively admitted patients older than 18 years at ICU University Hospital in Olomouc in the period from 1 January 2011 to 31 December 2015 who fulfilled the criteria of HAP. The aim was to determine the severity of the specific risk factors of early and late HAP. Risk factors were divided into factors from the patient and from the hospitalization. Furthermore, an assessment of their relationship to mortality.

The primary outcome was to evaluate the relationship between risk factors and the development of early/late onset HAP. Another outcome was assessed to evaluate the relation of risk factors early/late onset HAP and mortality. The crucial time for evaluating the presence of risk factors was their presence from hospital admission to the moment of fulfilling the criteria for pneumonia. Risk factors were divided into two groups, on factors of the patient (uncontrollable) and by the hospitalization (controllable). Factors of the patient were: gender (male/female), age at enrollment (years), Acute Physiology and Chronic Health Evaluation II (APACHE II) score, multi-organ failure presence (MOF), hypertension, ischemic heart disease (IHD) chronic renal insufficiency (CRI), continual use of renal replacement therapy (CRRT), acute renal insufficiency (ARI), diabetes mellitus (DM), Chronical Obstructive Pulmonary Disease (COPD), immunosuppression or leukopenia \<1.5x109/l, impaired consciousness with Glasgow coma scale (GCS) \<8 tracheotomy, head trauma/neurosurgery, abdominal surgery-thoracotomy. Side factors hospitalization were: aspiration into the lungs, urgent intubation, reintubated, sedation, bronchoscopy, nasogastric intubation, enteral feeding continuously/intermittently intolerance of enteral nutrition, physiotherapy, repeated transport of the patient from the ICU, length of hospital stay, length of mechanical ventilation, 30-day mortality.

Eligibility Criteria:
Inclusion Criteria:

* Hospital-Acquired Pneumonia
* Intensive Care patient
* X-ray signs of pneumonia

Exclusion Criteria:

* Age less than 18 years
* Negative culture findings in the airways
* Low quantity of culture findings